Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study

Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

NANETS (North American Neuroendocrine Tumor Society) Symposium

34th Annual Congress of the European Association of Nuclear Medicine (EANM)

ESMO (European Society for Medical Oncology) Congress

Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

American Society of Clinical Oncology (ASCO) Annual Meeting

Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)

Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer

Advanced Accelerator Applications to Build Targeted RadioLigand Therapy Production Facility in Indianapolis